论文部分内容阅读
[目的]研究胃癌患者血浆中基因表达检测的可行性,探讨基因p53和K-ras突变与临床病理间的关系。[方法]应用PCR-SSCP分析技术,检测62例胃癌患者血浆中K-ras癌基因的突变情况。[结果]62例胃癌患者外周血和门静脉血中的p53、K-ras突变阳性率分别为8.06%、4.83%和38.71%、33.87%;无、有肝转移患者p53、K-ras突变阳性率分别为24.49%、22.45%和92.30%、76.92%;门静脉血p53、K-ras突变阳性率分别为38.71%、33.87%和56.45%、62.90%。[结论]胃癌的发生发展与血浆中癌基因K-ras与抑癌基因p53的突变有关。
[Objective] To investigate the feasibility of detecting gene expression in plasma of patients with gastric cancer and to explore the relationship between the mutations of p53 and K-ras and clinical pathology. [Methods] The mutation of K-ras oncogene in plasma of 62 patients with gastric cancer was detected by PCR-SSCP. [Results] The positive rates of p53 and K-ras mutation in peripheral blood and portal vein blood of 62 patients with gastric cancer were 8.06%, 4.83% and 38.71%, 33.87% respectively. The positive rate of p53 and K-ras mutation in patients without liver metastasis 24.49%, 22.45% and 92.30%, 76.92% respectively. The positive rates of p53 and K-ras mutations in portal vein were 38.71%, 33.87% and 56.45% and 62.90% respectively. [Conclusion] The occurrence and development of gastric cancer are related to the mutation of plasma oncogene K-ras and tumor suppressor gene p53.